Lv3
260 积分 2026-03-10 加入
A dexamethasone‐free daratumumab–ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018‐02 phase II study
1个月前
已完结
Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody
1个月前
已完结
Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses
2个月前
已关闭
Targeting the BRAF V600E Mutation in Multiple Myeloma
2个月前
已完结
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
2个月前
已完结
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
2个月前
已完结
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
2个月前
已完结
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
2个月前
已完结
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
2个月前
已完结
皖公网安备34019202002308
